Less frequent radiological exams to avoid futile response assessments from 177-LuDOTATE therapy for patients with advanced neuroendocrine tumors
in Endocrine OncologySearch for other papers by Carolina C Marques in
Current site
Google Scholar
PubMed
Search for other papers by Angelo B Brito in
Current site
Google Scholar
PubMed
Search for other papers by Eduardo N Lima in
Current site
Google Scholar
PubMed
Search for other papers by Mauro D Donadio in
Current site
Google Scholar
PubMed
Search for other papers by Rachel Pimenta Riechelmann in
Current site
Google Scholar
PubMed
Background: 177-LuDOTATE is an effective but expensive treatment for neuroendocrine tumors (NETs). Reducing treatment-related costs, such as the number of images, could improve access of 177-LuDOTATE. We evaluated early radiological tumor progression and prognostic factors in pts with NETs treated with 177-LuDOTATE.
Methods: We retrospectively included all pts with NETs who received at least one cycle of 177-LuDOTATE. The primary endpoint was the rate of early radiological progression between cycles 2 and 3 (in 10 - 16 weeks). Secondary endpoints were progression-free survival (PFS) and overall survival (OS) according to prognostic factors (tumor grade, primary site, functioning syndrome, 177-LuDOTATE treatment line) in Cox proportional hazards models.
Results: The median number of 177-LuDOTATE cycles was 3 (range 1-6) among 59 patients included. Ten (17%) patients had early progression. Among 14 patients who received ≤ 2 cycles of 177-LuDOTATE, 10 (72%) stopped treatment due to disease progression, with 5 patients having a G2 (ki67: 5-25%) and 4, a G3 (ki67: 25-90%) NET. In the Cox multivariable analysis, higher grade (G2 or G3 vs G1) were significantly associated with inferior PFS and OS. The median PFS of G1, G2 and G3 NET pts were: 34.1, 11.7 and 6.1 months (p = 0.01), respectively.
Conclusions: It is feasible to perform imaging tests after 177-LuDOTATE completion for patients with indolent NETs, with the intent to reduce costs. For patients with more aggressive disease, such as those with higher G2 and G3 NETs, we advise to perform more frequent images during 177-LuDOTATE therapy.
Endocrine Oncology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
As an open-access journal, Endocrine Oncology articles are immediately available to read on publication, without restriction. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Feb 2021 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 169 | 169 | 169 |
| PDF Downloads | 77 | 78 | 77 |
Online ISSN: 2634-4793
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519